TABLE 1. Active clinical trials for adults with CLL.

Listed are currently accruing clinical trials using autologous CAR-modified T cells targeted to the CD19 antigen for patients with CLL.

Clinical Trial Identifier	CAR	Gene Transfer	Disease status	T cell Escal.	Conditioning Therapy	Trial Site
NCT00586391	19z* vs 1928z	γ-retrovirus	Relapsed	Yes	CY	Dallas, TX
NCT00709033	19z** vs 1928z	γ-retrovirus	Relapsed	Yes	CY	Dallas, TX
NCT00924326	1928z	γ-retrovirus	Relapsed	No	CY+FLU IL2***	Washington, DC
NCT00968760****	1928z	Electroporation SB-Transposase	Relapsed	Yes	BEAM+R ± IL2	Houston, TX
NCT01653717	1928z	Electroporation SB-Transposase	8 weeks from last chemo	Yes	CY+FLU	Houston, TX
NCT01416974	1928z	γ-retrovirus	MRD*****	Yes	CY	New York, NY
NCT00466531	1928z	γ-retrovirus	Relapsed	Yes	CY	New York, NY
NCT01029366	19BBz	lentivirus	Relapsed	No	Investigators Choice	Philadelphia, PA

MRD=Minimal Residual Disease. CY=Cyclophosphamide. FLU=Fludarabine. SB=Sleeping Beauty.

^*Patients are infused with a mixture of T cells modified with either the 19z or 1928z CAR.

^**Patients are infused with a mixture of T cells modified with either the 19z or 1928z CAR. The 19z CARs are transduced into EBV+ T cells, while the 1928z CARs are transduced into normal peripheral, polyclonal T cells.

^***IL2 is not given as a lymphodepleting agent but as a T cell growth factor

^****This is the only trial listed where the T cells are administered as part of an autologous stem cell transplant

^*****This trial is evaluating CAR-modified T cells as a consolidation regimen. Patients treated with an initial chemotherapy regimen that have residual disease after completing this regimen are infused with 1928z+ T cells.